Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis

Giunta, 2021, Molecular characterization of prostate cancers in the precision medicine era, Cancers, 13, 4771, 10.3390/cancers13194771 de Bono, 2020, Olaparib for metastatic castration-resistant prostate cancer, N Engl J Med, 382, 2091, 10.1056/NEJMoa1911440 Abida, 2020, Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study, Clin Cancer Res, 26, 2487, 10.1158/1078-0432.CCR-20-0394 Krishnakumar, 2010, The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets, Mol Cell, 39, 8, 10.1016/j.molcel.2010.06.017 Rouleau, 2010, PARP inhibition: PARP1 and beyond, Nat Rev Cancer, 10, 293, 10.1038/nrc2812 Asim, 2017, Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer, Nat Commun, 8, 374, 10.1038/s41467-017-00393-y Schiewer, 2012, Dual roles of PARP-1 promote cancer growth and progression, Cancer Discov, 2, 1134, 10.1158/2159-8290.CD-12-0120 Clarke, 2018, Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo- controlled, phase 2 trial, Lancet Oncol, 19, 975, 10.1016/S1470-2045(18)30365-6 Carr, 2021, Homologous recombination repair gene mutation characterization by liquid biopsy: a phase II trial of olaparib and abiraterone in metastatic castrate-resistant prostate cancer, Cancers, 13, 5830, 10.3390/cancers13225830 Moher, 2010, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement, Int J Surg, 8, 336, 10.1016/j.ijsu.2010.02.007 Higgins, 2011, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials, BMJ, 343, 10.1136/bmj.d5928 Higgins JPT, Green S, editors. Assessing the quality of a body of evidence. In: Cochrane handbook for systematic reviews of interventions, volume 5.1.0. New York, NY: John Wiley & Sons; 2011, p. 361–6. Mantel, 1959, Statistical aspects of the analysis of data from retrospective studies of disease, J Natl Cancer Inst, 22, 719 Higgins, 2002, Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice, J Health Serv Res Policy, 7, 51, 10.1258/1355819021927674 Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 1539, 10.1002/sim.1186 Saad, 2022, 1357O – Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC), Ann Oncol, 33, S1160, 10.1016/j.annonc.2022.07.1945 Chi, 2023, Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer, J Clin Oncol, 41, 3339, 10.1200/JCO.22.01649 Agarwal, 2023, TALAPRO-2: phase 3 study of talazoparib (TALA)enzalutamide (ENZA) versus placebo (PBO)ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 41 Mateo, 2020, Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial, Lancet Oncol, 21, 162, 10.1016/S1470-2045(19)30684-9 Elsesy, 2020, Second-generation antiandrogen therapy radiosensitizes prostate cancer regardless of castration state through inhibition of DNA double strand break repair, Cancers, 12, 2467, 10.3390/cancers12092467 Carreira, 2021, Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial, Cancer Discov, 11, 2812, 10.1158/2159-8290.CD-21-0007 Loehr, 2021, Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study, Clin Cancer Res, 27, 6677, 10.1158/1078-0432.CCR-21-2199 Chi, 2023, Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound, Clin Cancer Res, 29, 81, 10.1158/1078-0432.CCR-22-0931 Oya, 2022, 157O– Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC), Ann Oncol, 33, S1495, 10.1016/j.annonc.2022.10.194 Castro, 2023, J Clin Oncol, 41, 172, 10.1200/JCO.2023.41.6_suppl.172 LaFargue, 2019, Exploring and comparing adverse events between PARP inhibitors, Lancet Oncol, 20, e15, 10.1016/S1470-2045(18)30786-1 Nindra, 2023, Review of toxicities of PARP inhibitors in metastatic castrate resistant prostate cancer, Clin Genitourin Cancer, 21, 183, 10.1016/j.clgc.2022.07.005 Mandel, 2023, Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis, Eur Urol Focus, 9, 96, 10.1016/j.euf.2022.08.007 Rodrigues, 2018, Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer, J Clin Invest, 128, 5185, 10.1172/JCI125184 Sweeney, 2021, Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial, Lancet, 398, 131, 10.1016/S0140-6736(21)00580-8 Fenor de la Maza, 2022, Immune biomarkers in metastatic castration-resistant prostate cancer, Eur Urol Oncol, 5, 659, 10.1016/j.euo.2022.04.004 Dalmasso, 2022, Beyond BRCA: the emerging significance of DNA damage response and personalized treatment in pancreatic and prostate cancer patients, Int J Mol Sci, 23, 4709, 10.3390/ijms23094709